THERAPY DOSSIER · th-1f64aff50cd5

Maslinic acid

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06484543 ↗NAactive not recruiting

Brown Fat as Therapeutic Strategy for Obesity and Associated Metabolic Diseases Via Functional/Nutraceutical Approach - Molecular Mechanisms of Pentacyclic Triterpenes (BRACE)

Diabetes · Brown Adipose Tissue

Enrolment: 50 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29627448 ↗2018Reported benefit

Maslinic acid protects against lipopolysaccharide/d-galactosamine-induced acute liver injury in mice.

MouseEndotoxin/LPSBALB/cIntraperitoneal1 h before lipopolysaccharide and d-galactosamine challenge

Model: Acute liver injury induced by lipopolysaccharide plus d-galactosamine

Maslinic acid reduced histopathological liver damage, serum AST and ALT, inflammatory cytokines, MDA and myeloperoxidase in a dose-dependent manner, lowered hepatic NF-kappaB and raised Nrf2 and HO-1 expression.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…